跳至主要内容

A New Tool for Identifying Active Metabolites in Biological Systems

Active metabolomics is swiftly becoming a revolutionary tool in the realm of scientific research, providing us an in-depth perspective to the world of active metabolites in biological systems. Through its multi-disciplinary approach, active metabolomics, with a foundation in biochemistry, molecular biology, and computational biology, offers insights into the intricate networks of metabolites at play within biological organisms.

Active metabolites form the functional backbone within biological systems. They range from basic building blocks such as glucose and amino acids to signaling molecules such as hormones, neurotransmitters, and other biologically active entities. The identification and understanding of these metabolites are paramount for a comprehensive understanding of physiological functions in living organisms and unraveling complex biological processes.

Active metabolomics provides us with a breakthrough, allowing a systematic approach to studying active metabolites within organisms. From sampling to sample preparation, purification, qualitative and quantitative analysis using methodologies such as mass spectrometry or nuclear magnetic resonance (NMR), followed by data processing and bioinformatics analysis, active metabolomics enables a holistic understanding of metabolites and their intricate interplays.

In practice, active metabolomics requires the extraction and separation of metabolites from biological samples, followed by an analytical process using methods such as mass spectrometry, gas chromatography, or liquid chromatography. The generated data is then interpreted using computer-assisted data processing techniques, allowing for the identification of specific active metabolites, understanding their molecular structures, and exploring their metabolic pathways and mechanistic roles within biological systems.


In conclusion, the advent of active metabolomics not only helps elucidate the complex happenings within biological systems but also provides us with new perspectives and tools for the study of complex life phenomena. The deployment of this technique will undoubtedly furnish us with abundant and powerful means to delve into basic life science questions and addresses practical issues in medical health in the future.

The MetID team of Medicilon is composed of experienced scientists. We provide fast and reliable in vivo and in vitro MetID and reactive metabolite capture services. We also support new drug screening and domestic and oversees IND filings. Since the establishment of MetID team, Medicilon has successfully completed multiple different types of research projects for clients, including challenging peptide MetID research.

评论

此博客中的热门博文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...

Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002

  On July 20, 2020, DAC Biotech’s new   ADC drug development , TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed   preclinical pharmacokinetic  and toxicological studies in this project, accelerating the development process. DAC-002 is an ADC anti-Trop2 monoclonal antibody conjugated by an intelligent ligand against Tubulysin B analogue. It is used to treat Trop2 triple negative breast cancer, small cell lung cancer, non-small cell lung cancer and pancreatic cancer.Trop2 can promote the proliferation, invasion, metastasis and diffusion of tumor cells, and its high expression is closely related to the shortening of survival time and poor prognosis of tumor patients. Therefore, it is of great significance to study anti-tumor drugs targeted by Trop2. Reference: Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use Medicilon As...

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...